Company news

Travere Therapeutics, Inc. news in 2024

Travere Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Travere Therapeutics to Present at Upcoming Investor Conferences

November 24, 2024

Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

November 11, 2024

Travere Therapeutics Announces Proposed Public Offering of Common Stock

November 6, 2024

Travere Therapeutics Announces Pricing of Public Offering of Common Stock

November 6, 2024

Travere Therapeutics Reports Third Quarter 2024 Financial Results

October 30, 2024

Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024

October 25, 2024

Travere Therapeutics to Report Third Quarter 2024 Financial Results

October 20, 2024

Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

October 16, 2024

CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

October 16, 2024

Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024

October 13, 2024

Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up

September 25, 2024

Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference

September 9, 2024

Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

September 4, 2024

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024

August 21, 2024

Travere Therapeutics Reports Second Quarter 2024 Financial Results

July 31, 2024

Travere Therapeutics to Report Second Quarter 2024 Financial Results

July 24, 2024

Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

July 7, 2024

Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress

May 8, 2024

Travere Therapeutics Reports First Quarter 2024 Financial Results

May 5, 2024

Travere Therapeutics to Report First Quarter 2024 Financial Results

April 28, 2024

Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

April 23, 2024

CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

April 23, 2024

Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International

April 3, 2024

Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association

April 2, 2024

Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)

March 10, 2024

Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy

February 22, 2024

CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy

February 22, 2024

Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

February 14, 2024

Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference

January 31, 2024

Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations

January 24, 2024

Travere Therapeutics Provides Corporate Update and 2024 Outlook

January 7, 2024

Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 1, 2024

Calls in 2024

Decks in 2024